HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MBIO
Mustang Bio, Inc.
There isn't enough reported data to score MBIO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MBIO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
MBIO's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MBIO PE Valuation
MBIO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MBIO Forward outlook
There aren't enough analyst estimates for MBIO to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
MBIO has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus MBIO down 101%.
MBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$78.00 | +$314.00 |
| Q2 2024 | -$137.50 | +$328.00 |
| Q1 2024 | -$220.00 | +$288.00 |
| Q4 2023 | -$300.00 | +$262.50 |
| Q3 2023 | -$392.00 | +$208.00 |
| Q2 2023 | -$465.50 | +$142.00 |
| Q1 2023 | -$508.00 | +$77.00 |
| Q4 2022 | -$562.50 | +$7.50 |
MBIO lost $0.52 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MBIO Quarterly Revenue
MBIO and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
MBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$876K | -$58K |
| Q2 2026 | -$967K | +$372K |
| Q1 2026 | -$1M | +$381K |
| Q4 2025 | -$1.7M | +$279K |
| Q3 2025 | -$818K | +$939K |
| Q1 2025 | -$1.4M | +$3.9M |
| Q4 2024 | -$2M | +$5.3M |
| Q3 2024 | -$1.8M | +$10.3M |
MBIO has burned cash in almost every quarter: −$5M over the past year, against −$6M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +2.8K shares |
| 1 year | +68% | +2.7M shares |
| 3 years | +4044% | +6.6M shares |
| 5 years | +5669% | +6.6M shares |
| Available history | +13909% | +6.7M shares |
MBIO has 7M diluted shares, up 68% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MBIO Net Leverage
MBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 24.2 | Neutral |
MBIO's weekly RSI is 39 (neutral) and its Stochastic is 24 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MBIO PE vs Healthcare Sector
MBIO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.42 | 9.5% above |
| 20 week MA | $0.52 | 12% below |
| 50 week MA | $0.73 | 37% below |
| 100 week MA | $1.59 | 71% below |
| 200 week MA | $64.1 | 99% below |
MBIO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over MBIO on returns for 2026, with the stronger performance.
MBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2,865.0 | $3,135.0 | +9.4% |
| 2021 | $3,135.0 | $1,402.5 | -55% |
| 2022 | $1,402.5 | $288.2 | -79% |
| 2023 | $288.2 | $67.5 | -77% |
| 2024 | $67.5 | $9.20 | -86% |
| 2025 | $9.20 | $1.02 | -89% |
| 2026 YTD | $1.02 | $0.46 | -55% |
MBIO has finished five years in a row lower, and it's down 55% so far in 2026.